AbCellera Biologics Inc. ABCL Gain (Loss) on Contingent Consideration and Investments
Gain (Loss) on Contingent Consideration and Investments at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept abcl:GainLossOnContingentConsiderationAndInvestments.
The official record: AbCellera Biologics Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s gain (loss) on contingent consideration and investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s gain (loss) on contingent consideration and investments?
- AbCellera Biologics Inc. (ABCL) reported gain (loss) on contingent consideration and investments of -$1.13M in Q4 2025.
- How has AbCellera Biologics Inc.'s gain (loss) on contingent consideration and investments changed year-over-year?
- AbCellera Biologics Inc.'s gain (loss) on contingent consideration and investments decreased by 107.0% year-over-year, from $16.18M to -$1.13M.
- What is the long-term trend for AbCellera Biologics Inc.'s gain (loss) on contingent consideration and investments?
- Over 3 years (2022 to 2025), AbCellera Biologics Inc.'s gain (loss) on contingent consideration and investments has grown at a 13.6% compound annual growth rate (CAGR), from -$3.09M to -$4.53M.
- What does gain (loss) on contingent consideration and investments mean?
- This reflects the non-cash impact of changes in the fair value of contingent consideration liabilities or investment holdings. It captures fluctuations in the estimated payouts for acquisitions or the market value of strategic investments. Monitoring this helps investors isolate operational performance from volatile accounting adjustments related to financial instruments.